霍奇金淋巴瘤国际个人护理研究 (HoLISTIC) 联盟的 A-HIPI 模型于 2022 年针对晚期经典霍奇金淋巴瘤 (cHL) 开发，可预测新诊断患者的 5 年内生存率。这项研究验证了其在巴西霍奇金淋巴瘤登记中的表现。到 2022 年，巴西 HL 登记处纳入了 1357 名 cHL 患者，中位随访时间为 5 年。使用 A-HIPI 模型方程计算 5 年无进展生存期 (PFS) 和总生存期 (OS) 的概率。歧视（Harrell C 统计/Uno C 统计）和校准措施评估了外部验证和校准。超出允许范围的实验室值被排除，反映了最初的 A-HIPI 分析。共有 694 名晚期 cHL 患者符合最初的纳入标准（年龄 18-65 岁，IIB-IV 期）。中位年龄为 31 岁； 46.3%为女性。分期分布为IIB（33.1%）、III（27.4%）、IV（39.5%）。巨块病占32.6%。五年 PFS 和 OS 分别为 68.4% 和 86.0%。 Harrell C 统计量的 PFS 为 0.60，OS 为 0.69，Uno C 统计量的 PFS 为 0.63，OS 为 0.72。校准图显示了经过良好校准的预测，5 年 OS 和 PFS 的校准斜率分别为 0.91 和 1.03。尽管患者、临床特征和社会经济因素不同，但基线预测工具在巴西队列中表现良好，表现出充分的区分和校准。这支持了其在不同环境下的可靠性。© 2024 英国血液学会和 John Wiley

The Hodgkin lymphoma International Study for Individual Care (HoLISTIC) Consortium's A-HIPI model, developed in 2022 for advanced-stage classical Hodgkin lymphoma (cHL), predicts survival within 5 years amongst newly diagnosed patients. This study validates its performance in the Brazilian Hodgkin lymphoma registry. By 2022, the Brazilian HL registry included 1357 cHL patients, with a median 5-year follow-up. Probabilities for 5-year progression-free survival (PFS) and overall survival (OS) were calculated using A-HIPI-model equations. Discrimination (Harrell C-statistic/Uno C-statistic) and calibration measures assessed external validation and calibration. Lab values beyond the allowed range were excluded, mirroring the initial A-HIPI analysis. A total of 694 advanced-stage cHL patients met the original inclusion criteria (age 18-65 years, Stage IIB-IV). Median age was 31 years; 46.3% were females. Stage distribution was IIB (33.1%), III (27.4%), IV (39.5%). Bulky disease in 32.6%. Five-year PFS and OS were 68.4% and 86.0%, respectively. Harrell C-statistics were 0.60 for PFS and 0.69 for OS, and Uno C-statistics were 0.63 for PFS and 0.72 for OS. Calibration plots demonstrated well-calibrated predictions with calibration slopes of 0.91 and 1.03 for 5-year OS and PFS, respectively. Despite differing patient, clinical characteristics, and socioeconomic factors, the baseline prediction tool performed well in the Brazilian cohort, demonstrating adequate discrimination and calibration. This supports its reliability in diverse settings.© 2024 British Society for Haematology and John Wiley & Sons Ltd.